Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Saint Louis University

Neither a doctor nor a teaching hospital

Research payments

$4,180,859

639 payments

Through program year 2025, Saint Louis University is reported as receiving $4,180,859 in research payments, across 639 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $867,048 167
2024 Research $591,616 100
2023 Research $529,266 61
2022 Research $780,652 90
2021 Research $638,989 49
2020 Research $340,320 101
2019 Research $432,968 71

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $671,087 3 payments
  2. bioMerieux $530,359 29 payments
  3. Argenx US, Inc. $427,903 179 payments
  4. Merck Sharp & Dohme Corporation $369,981 41 payments
  5. E.R. Squibb & Sons, L.L.C. $301,854 21 payments
  6. Seattle Genetics, Inc. $270,744 15 payments
  7. Eli Lilly and Company $206,604 12 payments
  8. Amgen Inc. $141,303 6 payments
  9. AbbVie, Inc. $131,579 42 payments
  10. AstraZeneca Pharmaceuticals LP $84,210 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Characterizing the Relationship Between Liver Fibrosis and its Progression Assessed by Biopsy and Plasma Biomarkers of Inflammation and Elastin Turnover in PiZZ Patients with AAT Deficiency $671,087 3 payments
  2. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in Participants with Incurable,Non-metastatic Hepatocellular Carcinoma LEAP-012 $365,805 9 payments
  3. Performance Evaluation of the VIDAS TB-IGRA Assay $277,302 7 payments
  4. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $245,628 10 payments
  5. VIDAS TB IGRA NILOR Study $152,559 18 payments
  6. Performance Evaluation of the VIDASTB-IGRAAssay. $100,499 4 payments
  7. Phase IIB Study - F3 24 wk $86,035 2 payments
  8. Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis $84,359 5 payments
  9. ASTRO P3 AD Adolescent Mono $80,852 2 payments
  10. A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid $72,512 20 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $77,399 6 payments
  2. Overhead $30,010 2 payments
  3. Other $20,490 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record